Mouse Monoclonal C1QA Antibody

The C1QA antibody targets the C1q A chain, a critical component of the C1 complex in the complement system’s classical pathway. C1q, a hexameric protein composed of A, B, and C polypeptide chains, initiates immune responses by binding to antigen-antibody complexes or pathogen surfaces, triggering complement activation and pathogen clearance. C1QA, specifically, contributes to the structural and functional integrity of C1q. Antibodies against C1QA are widely used in research to study complement-mediated processes, including immune complex diseases, autoimmune disorders (e.g., systemic lupus erythematosus), and neurodegenerative conditions linked to aberrant complement activity. They enable detection of C1q expression, localization, and interactions in tissues or biofluids, aiding in mechanistic studies of diseases. Dysregulation of C1q is implicated in pathologies like lupus nephritis and Alzheimer’s disease, where C1QA antibodies may serve as diagnostic or prognostic tools. Additionally, therapeutic strategies targeting C1q (e.g., inhibitory antibodies) are being explored to modulate complement overactivation. C1QA antibodies thus play a pivotal role in elucidating complement biology, bridging basic research and clinical applications in inflammation and autoimmunity.